European Archives - Page 383 of 1423 - European Medical Journal

Rethinking Pregnancy Guidelines for Women with Peri-Partum Cardiomyopathy

A groundbreaking study from the European Society of Cardiology suggests that pregnancy in women with peri-partum cardiomyopathy (PPCM) may not be as high-risk as previously believed.

HBA CEO Mary Stutts

The HBA’s Mary Stutts on tackling bias for better women’s health

Mary Stutts, CEO, HBA, unpacks the key findings of a report exposing critical gaps in doctors’ understanding of women’s health.

The Link Between Obesity and Overactive Bladder Syndrome

These findings suggest that strategies targeting visceral fat reduction may aid in overactive bladder management.

Obstructive Sleep Apnoea Associated with Higher Suicide Attempts

A nationwide study from South Korea has found a concerning link between obstructive sleep apnea and suicidal behaviors.

New AI Model Enhances MRI Segmentation for Medical Applications

A groundbreaking automated MRI segmentation model has been developed to provide accurate and robust segmentation of major anatomical structures across all MRI sequences.

Unraveling the Genetic and Phenotypic Complexity of Psychosis in Epilepsy

Explore how genetic and phenotypic features of psychosis in epilepsy can guide precision medicine.

Gender and Age Affect Bleeding Risk in Anticoagulant Treatment

Bleeding risk from anticoagulants varies by gender and age in venous thromboembolism treatment, especially during the initial phase.

Leisure-Time Exercise Linked to Lower Risk of Type 2 Diabetes, Study Finds

Study shows that engaging in moderate to vigorous physical activity during leisure time is associated with a reduced risk of Type 2 diabetes.

Vitamin E Compound Enhances Tumour Immunology and Treatment

The ability to pharmacologically degrade fat mass and obesity-associated protein represents a promising avenue for enhancing anti-tumour immunity.

The world

EMA grants accelerated review to Gilead’s PrEP drug

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV prevention.